Preexposure Prophylaxis for HIV Infection among African Women
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. METHODS: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily. The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. RESULTS: HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estimated hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P=0.81). The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P=0.04, P<0.001, and P=0.03, respectively). Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P=0.051). Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion. The study was stopped early, on April 18, 2011, because of lack of efficacy. CONCLUSIONS: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low. (Supported by the U.S. Agency for International Development and others; FEM-PrEP ClinicalTrials.gov number, NCT00625404.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Patterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355
Self-citationPre-exposure prophylaxis for HIV prevention: how to predict success
Kashuba, A. D. M., Patterson, K. B., Dumond, J. B., & Cohen, M. S. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61852-7 · Cited by 72
Self-citation
Cited by
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J.-M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C., Le Gall, J.-M., Cua, E., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,633
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
“(%)§ 301 (6) 68 (7) 54 (5) 66 (7) 62 (6) 51 (5)”
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapia, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,208
Self-citationEffectiveness and safety of oral HIV preexposure prophylaxis for all populations
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O’Reilly, K. R., Koechlin, F. M., Rodolph, M., Hodges-Mameletzis, I., & Grant, R. M. (2016) · AIDS · doi:10.1097/qad.0000000000001145 · Cited by 993
Self-citationHIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Kharsany, A. B. M., & Karim, Q. A. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010034 · Cited by 980
HIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Liu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4683 · Cited by 602
Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.
Nel, A., van Niekerk, N., Kapiga, S., Bekker, L.-G., Gama, C., Gill, K., Kamali, A., Kotze, P., Louw, C., Mabude, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602046 · Cited by 479
Self-citationMolina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., et al. (2017) · Science · doi:10.1126/science.aai9383 · Cited by 428
Auerbach, J. D., Kinsky, S., Brown, G., & Charles, V. (2015) · AIDS Patient Care and STDs · doi:10.1089/apc.2014.0142 · Cited by 392
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., et al. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000489577.60775.40 · Cited by 372
Donnell, D., Baeten, J. M., Bumpus, N. N., Brantley, J., Bangsberg, D. R., Haberer, J. E., Mujugira, A., Mugo, N., Ndase, P., Hendrix, C., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000172 · Cited by 358
Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis
Morrison, C. S., Chen, P.-L., Kwok, C., Baeten, J. M., Brown, J., Crook, A. M., Van Damme, L., Delany-Moretlwe, S., Francis, S. C., Friedland, B. A., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001778 · Cited by 355
Self-citationWomen and HIV in Sub-Saharan Africa
Ramjee, G., & Daniels, B. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-30 · Cited by 341
Past, present and future: 30 years of HIV research
Barré-Sinoussi, F., Ross, A. L., & Delfraissy, J.-F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3132 · Cited by 332
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
Haberer, J. E., Bangsberg, D. R., Baeten, J. M., Curran, K., Koechlin, F., Amico, K. R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000647 · Cited by 319
Calabrese, S. K., & Underhill, K. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302816 · Cited by 313
Krakower, D., Ware, N., Mitty, J. A., Maloney, K., & Mayer, K. H. (2014) · AIDS and Behavior · doi:10.1007/s10461-014-0839-3 · Cited by 305
Cottrell, M. L., Yang, K. H., Prince, H. M. A., Sykes, C., White, N., Malone, S., Dellon, E. S., Madanick, R. D., Shaheen, N. J., Hudgens, M. G., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw077 · Cited by 300
Self-citationApplying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia
Kelley, C. F., Kahle, E., Siegler, A., Sanchez, T., del Rio, C., Sullivan, P. S., & Rosenberg, E. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ664 · Cited by 298
Anderson, P. L., Liu, A. Y., Castillo-Mancilla, J. R., Gardner, E. M., Seifert, S. M., McHugh, C., Wagner, T., Campbell, K., Morrow, M., Ibrahim, M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01710-17 · Cited by 272
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
Deutsch, M. B., Glidden, D. V., Sevelius, J., Keatley, J., McMahan, V., Guanira, J., Kallas, E. G., Chariyalertsak, S., & Grant, R. M. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00206-4 · Cited by 268
Self-citationChou, R., Evans, C., Hoverman, A., Sun, C., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019) · JAMA · doi:10.1001/jama.2019.2591 · Cited by 266
O Murchu, E., Marshall, L., Teljeur, C., Harrington, P., Hayes, C., Moran, P., & Ryan, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2020-048478 · Cited by 263
HIV Preexposure Prophylaxis: A Review
Riddell, J., Amico, K. R., & Mayer, K. H. (2018) · JAMA · doi:10.1001/jama.2018.1917 · Cited by 258
van der Straten, A., Stadler, J., Montgomery, E., Hartmann, M., Magazi, B., Mathebula, F., Schwartz, K., Laborde, N., & Soto-Torres, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089118 · Cited by 258
Celum, C. L., Delany‐Moretlwe, S., Baeten, J. M., van der Straten, A., Hosek, S., Bukusi, E. A., McConnell, M., Barnabas, R. V., & Bekker, L. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25298 · Cited by 257
Torrone, E. A., Morrison, C. S., Chen, P.-L., Kwok, C., Francis, S. C., Hayes, R. J., Looker, K. J., McCormack, S., McGrath, N., van de Wijgert, J. H. H. M., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002511 · Cited by 256
Tseng, A., Seet, J., & Phillips, E. J. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12403 · Cited by 256
Calabrese, S. K., Earnshaw, V. A., Underhill, K., Hansen, N. B., & Dovidio, J. F. (2014) · AIDS and Behavior · doi:10.1007/s10461-013-0675-x · Cited by 254
Pleuhs, B., Quinn, K. G., Walsh, J. L., Petroll, A. E., & John, S. A. (2020) · AIDS Patient Care and STDs · doi:10.1089/apc.2019.0189 · Cited by 253
Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
Kirtane, A. R., Abouzid, O., Minahan, D., Bensel, T., Hill, A. L., Selinger, C., Bershteyn, A., Craig, M., Mo, S. S., Mazdiyasni, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02294-6 · Cited by 227
Polis, C. B., Curtis, K. M., Hannaford, P. C., Phillips, S. J., Chipato, T., Kiarie, J. N., Westreich, D. J., & Steyn, P. S. (2016) · AIDS · doi:10.1097/qad.0000000000001228 · Cited by 196
Polymer-based nanocarriers for vaginal drug delivery
das Neves, J., Nunes, R., Machado, A., & Sarmento, B. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.004 · Cited by 138
Lorenzetti, L., Dinh, N., van der Straten, A., Fonner, V., Ridgeway, K., Rodolph, M., Schaefer, R., Schmidt, H. A., & Baggaley, R. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26107 · Cited by 89
Kovarova, M., Council, O. D., Date, A. A., Long, J. M., Nochii, T., Belshan, M., Shibata, A., Vincent, H., Baker, C. E., Thayer, W. O., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005075 · Cited by 77
Curran, K., Mugo, N. R., Kurth, A., Ngure, K., Heffron, R., Donnell, D., Celum, C., & Baeten, J. M. (2013) · AIDS and Behavior · doi:10.1007/s10461-013-0510-4 · Cited by 42
“Adherence to PrEP is key for effective HIV prevention, and understanding patterns of adherence related to sexual behavior may be especially important [4–6].”
Bhardwaj, S., Carter, B., Aarons, G. A., & Chi, B. H. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-015-0260-1 · Cited by 42
Past, Present, and Future Drug Delivery Systems for Antiretrovirals
Kirtane, A. R., Langer, R., & Traverso, G. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.015 · Cited by 28
Topical microbicides and HIV prevention in the female genital tract.
Cottrell, M. L., & Kashuba, A. D. M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.292 · Cited by 22
“These data suggested less than daily use for the majority of participants.(6,67) Excluding TDF2 (>30% attrition rate) and the Tenofovir Bangkok Study (directly observed dosing),(5,68) only Partners PrEP, demonstrated high adherence rates with detectable tenofovir concentrations in 82% of participants providing samples…”
BackgroundSelf-citationMugwanya, K. K., Palayew, A., Schaafsma, T., Irungu, E. M., Bukusi, E., Mugo, N., Morton, J., Odoyo, J., Ngure, K., Baeten, J. M., et al. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26137 · Cited by 16
Metadata
- Authors
- Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., Temu, L., Monedi, M. C., Mak'Oketch, P., Makanda, M., Reblin, I., Makatu, S. E., Saylor, L., Kiernan, H., Kirkendale, S., Wong, C., Grant, R., Kashuba, A., Nanda, K., Mandala, J., Fransen, K., Deese, J., Crucitti, T., Mastro, T. D., & Taylor, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-08-02
- Volume
- 367
- Issue
- 5
- Pages
- 411-422
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168251450
- Cited by
- 1,603
- References
- 5
- FWCI
- 111.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.